Article Text

Download PDFPDF
Efficacy of a canarypox virus-vectored vaccine against feline leukaemia
  1. H. Poulet, DVM1,
  2. S. Brunet, PhD1,
  3. C. Boularand, DVM1,
  4. A. L. Guiot, DVM, PhD1,
  5. V. Leroy, BSc1,
  6. J. Tartaglia, PhD2,
  7. J. Minke, DVM, PhD1,
  8. J. C. Audonnet, DVM, PhD1 and
  9. P. Desmettre, DVM1
  1. 1 Merial, Laboratoire de Lyon Gerland, 254 rue Marcel Merieux, 69007 Lyon, France
  2. 2 Aventis Pasteur, 1755 Steeles Avenue West, Toronto, Ontario, M2R 3T4, Canada


Canarypox virus recombinant vaccines have a unique efficacy and safety profile for the vaccinated host because the canarypox virus is non-replicative in mammalian hosts. After the vaccination of a mammalian species, recombinant canarypox viruses express the inserted genes but cannot multiply in the host. They stimulate a strong immune response in the absence of any virus amplification in the host or any viral spread into the environment. A new canarypox-based recombinant vaccine is the canarypox-feline leukaemia virus (FeLV) vaccine (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes. This paper describes experiments which demonstrate that it is effective against any oronasal FeLv challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe ‘in-contact’ challenge. Furthermore, the canarypox virus-FeLv vaccine was effective without an adjuvant.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.